# Treatment for Post Acute COVID-19 Syndrome

> **NCT05507372** · NA · UNKNOWN · sponsor: **Applied Biology, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Tinnitus, Subjective

## Interventions

- **DRUG:** Pimozide 1 MG

## Key facts

- **NCT ID:** NCT05507372
- **Lead sponsor:** Applied Biology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507372, "Treatment for Post Acute COVID-19 Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05507372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*